论文部分内容阅读
目的探讨克力芝在艾滋病病毒(HIV)感染妊娠妇女中抗病毒治疗(ART)的效果和安全性。方法采集2011年1月至2016年6月,在北京佑安医院性病艾滋病门诊,接受基于克力芝的三联抗病毒治疗的HIV感染妊娠妇女的临床资料,分析ART的疗效与安全性。结果 210例HIV感染孕妇基线时CD4~+T淋巴细胞(简称CD4细胞)计数为(365±171)个/μL,治疗24周时CD4细胞计数为(522±198)个/μL,治疗48周时CD4细胞计数为(546±203)个/μL,与基线相比差异有统计学意义(P均<0.05);病毒载量检测不到者所占的比例在基线、24周和48周时分别为12.4%、91.0%和96.7%,与基线相比差异有统计学意义(P均<0.05);胃肠道反应、贫血和血脂异常发生率分别为16.2%、12.4%和7.6%,无严重不良反应发生。结论基于克力芝的三联抗病毒治疗对于HIV感染孕妇疗效显著,安全性良好,可在HIV感染妊娠妇女中进一步推广。
Objective To investigate the efficacy and safety of Creudirin in anti-virus therapy (ART) in pregnant women infected with HIV. Methods From January 2011 to June 2016, clinical data of HIV-infected pregnant women receiving triple triple antiviral therapy based on Creutzfeldt-Jakob was collected from the STD / AIDS clinic of You’an Hospital in Beijing to analyze the efficacy and safety of ART. Results 210 pregnant women with HIV infection had a baseline count of CD4 + T lymphocytes (CD4 ± T cells) of 365 ± 171 cells / μL at baseline and a mean CD4 count of 522 ± 198 cells / μL at 24 weeks of treatment for 48 weeks (546 ± 203) / μL, the difference was statistically significant compared with the baseline (all P <0.05); the proportion of undetectable viral load in the baseline, 24 weeks and 48 weeks (12.4%, 91.0% and 96.7% respectively) (P <0.05). The rates of gastrointestinal reactions, anemia and dyslipidemia were 16.2%, 12.4% and 7.6% Serious adverse reactions occur. Conclusions Triallylantivirus therapy based on Kelixi has obvious curative effect on pregnant women with HIV infection and good safety. It can be further popularized in HIV-infected pregnant women.